

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 December 2002 (05.12.2002)

PCT

(10) International Publication Number
WO 02/096474 A1

(51) International Patent Classification⁷: **A61L 24/00**,
27/44, 27/54, A61F 2/44, A61L 27/50

(21) International Application Number: PCT/IB02/01860

(22) International Filing Date: 28 May 2002 (28.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
VI2001A000126 30 May 2001 (30.05.2001) IT

(71) Applicants (*for all designated States except US*):
TECRES S.P.A. [IT/IT]; Via Andrea Doria, 10, I-37066
Sommacampagna (IT). **SOFFIATI, Renzo** [IT/IT]; Via
Casotti, 32, I-37054 Nogara (IT).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **ROBOTTI, Pier-
francesco** [IT/IT]; Viale della Repubblica, 37, I-37126
Verona (IT).

(74) Agent: **MAROSCIA & ASSOCIATI SRL**; Corso Palla-
dio, 42, I-36100 Vicenza (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: BONE CEMENT CONTAINING COATED RADIOPAQUE PARTICLES AND ITS PREPARATION



(57) Abstract: An acrylic radiopaque bone cement for orthopaedic use comprises a solid phase composed of a mixture of at least one poly(methyl acrylate)-based polymer, one free-radical polymerization initiator and one or more substances opaque to X rays, and a liquid phase substantially composed of a mixture of at least one monomer, one accelerator and one stabilizer. The radiopaque substances comprise metallic tungsten and tantalum particles, compounds or mixtures thereof, covered with a polymer coating compatible with said bone cement. The coating layer of the particles of radiopaque substances is an acrylic polymer based on poly(methyl methacrylate). The amount

of radiopacifying element is between 1 and 20 % by weight, relative to the solid phase, preferably between 2 % and 5 % by weight, relative to the solid phase. The solid phase may additionally comprise one or more pharmacologically active substances. The method for its preparation consists in preparing the radiopacifying material by coating the metal particles with a layer of a polymer which is compatible with the matrix and exhibits oxygen barrier properties such that said layer does not dissolve completely in the liquid phase so as to keep its oxygen barrier properties at least partly unchanged.



WO 02/096474 A1

BONE CEMENT CONTAINING COATED RADIOPAQUE PARTICLES AND ITS PREPARATION

Technical Field

5

The present invention relates to the field of bone cements and specifically concerns a radiopaque acrylic bone cement having improved mechanical characteristics and a method for its preparation.

10 The bone cement according to the invention is therefore suitable for use advantageously in surgery where the combination of a high degree of radiopacity and notable mechanical strength are required.

More particularly, the present invention relates to a bone cement which is suitable
15 in particular for applications in vertebroplasty, cranioplasty, maxillofacial surgery and for fixing prostheses in orthopaedic surgery.

Background Art

20 In the orthopaedic surgery sector, bone cements composed of a mixture of resins biocompatible with the bone tissues are known and commonly used for stably fixing prostheses of different types in a wide range of locations on the skeleton or for restoring the continuity of tissues.

The most commonly used resins belong to the acrylic materials. The more widely used bone cements are composed of two phases, a liquid phase substantially composed of methyl methacrylate with an addition of N,N-dimethyl-p-toluidine as accelerator and hydroquinone as stabilizer, and a solid phase composed of a dry powder substantially composed of poly(methyl methacrylate) with a peroxide, usually benzoyl peroxide, as polymerization initiator. At the moment of use, the two phases are mixed, the polymer powder representing the solid phase is dissolved in the monomer present in the liquid phase, giving a liquid viscous solution. In the meantime, the N,N-dimethyl-p-toluidine causes the peroxide to decompose with the formation of free radicals which initiate the polymerization reaction, resulting in hardening of the mixture.

In addition to poly(methyl methacrylate), bone cements are known which contain a solid phase containing resins of the poly(ethyl methacrylate), poly(butyl methacrylate), poly(methyl methacrylate/styrene) types and/or copolymers thereof, which belong to the class of acrylic resins.

The effect of the bone cement consists in completely filling the voids present between the prostheses and the bone cavity prepared for implantation thereof, so as to ensure mechanical anchoring and a perfect fit of the bone implant.

The mechanical strength of the hardened cement thus obtained is not as high as that of the original bone tissues. Indeed, as a result of the considerable loads or as a result of fatigue stress at a high cycle number, the bone cement fillings can

give way and fracture. The modification of such fillings with time, their eventual flaking-off and their mechanical weakening must therefore be able to be detected and monitored, for example using standard radiological and tomographic techniques.

5

Since the synthetic base resin is transparent to X rays, the bone cement must be rendered opaque by adding suitable inorganic biocompatible substances.

The opacity to X rays of the elements increases substantially in proportion to their atomic weight. In general, especially for the heavier elements, their toxicity also increases. In medicine the known and most commonly used contrast agents are iodine, either in elemental or bonded form, bismuth in the form of carbonate and barium in the form of sulphate.

15 By using compounds such as salts or oxides, the radiopaque element constitutes only a portion of the additive. For example, the metal amounts to only 58% of barium sulphate, the remaining material being substantially transparent to X rays.

In the known bone cements, such radiopacifying materials usually consist of barium sulphate or zirconium oxide additives, in an amount of about 10% by weight, relative to the dry polymer.

Such additives, which introduce discontinuities in the polymer, weaken further the mechanical properties of the hardened cement, increasing the risk of failure and

frequency of fracturing or flaking off.

With the aim of reducing such disadvantages, the teachings of US patent US-A-5,795,922 propose encapsulation of the radiopacifying substance, in this case
5 selected from the group consisting of barium salts, zirconium oxide and bismuth glasses, in microcapsules of a compatible polymer material. During formation of the bone cement, the polymer material dissolves completely in the liquid phase releasing its contents, the radiopaque substance, which is enveloped by the polymer being formed.

10

These known bone cements are not suitable for the treatment of certain disorders, for example in the case of vertebroplasty.

Indeed, in the case of disorders of the general tumour type, in which an emptying
15 of the vertebra structure is produced, the latter loses its mechanical strength and collapses under the body weight, resulting in crushing of the nerve endings, causing intense suffering of the patient and a partial loss of motor function.

At the present time, in accordance with the prior art hitherto, such disorders are
20 treated with prostheses, metal plates or by administering analgesics.

A further known technique for such disorders consists in opening the vertebra, introducing the bone cement of the type described above, and closing it again. The hardened bone cement substitutes the missing part of the vertebra.

Recently, a new technique has been proposed which consists in injecting liquid bone cement, by means of a needle, inside the vertebra, thus avoiding the invasive surgical intervention referred to above.

5

This technique requires the use of a low-viscosity liquid bone cement so as to be able to inject it easily by means of a needle which may have a diameter of even less than 2 mm.

- 10 This operation is complicated and not free of risks since an error in positioning of the cement could result in a contact of the resin with the nerve endings of the spinal column, resulting in a paralysis of the patient or in a substantial increase in pain, owing to the insertion of protrusions in direct contact with the nerve centres which pass through the spinal column.

15

- In order to be able to perform this operation with absolute safety, the surgeon must be well-informed of the state of progress of the injection, which is controlled in real time by means of X rays. Since the time during which monitoring must take place is quite long, usually several hours, the intensity of exposure to the radiation must
20 be extremely low. Accordingly, it is not possible to use radiological or tomographic techniques involving significant radiation doses, but instead fluoroscopic techniques in which the patient is subjected to low-intensity X rays must be used.

The known bone cements described above, which are particularly suitable for the

fixing of prostheses, have proved to be insufficiently opaque to low-intensity X rays, poorly visible, practically transparent and substantially unsuitable for performing the injection with adequate safety.

- 5 The medico-scientific literature has reported several cases in which the surgeon has added an appreciable quantity of the radiopacifying contrast agent barium sulphate of up to 30-40% by weight, so as to render the cement used sufficiently radiopaque,.
- 10 On the other hand, the use of a metal in the form of salt has the consequence that only 58% by weight of the material introduced has an actual radiopacifying effect.

The presence of a voluminous quantity of powdery radiopacifier in the acrylic matrix increases the probability of initiating fractures and thus undermines the
15 integrity of the structure and jeopardizes the mechanical strength of the material in the long run (fatigue strength). This phenomenon is confirmed even in those cases in which the static performances comply with the minimum requirements of the ISO standard 5833.

- 20 In any case, this benefits the patient, but the intervention cannot guarantee that the expected result will be maintained over a long period, since the reinforcing structure is extremely weak.

The medico-scientific literature has described other cases in which the surgeon

adds to the bone cement of the type described above containing approximately 10% by weight of barium sulphate, relative to the dry polymer, or approximately 15% by weight of zirconium oxide, relative to the dry polymer, a quantity of powdery tungsten amounting to about 2% by weight as further radiopacifier.

5

The addition of about 9% by weight of tantalum powder to a bone cement devoid of radiopacifiers is likewise known.

In all abovementioned cases, the addition is made directly by the surgeon, shortly
10 before the intervention, under his responsibility and using a non-certified material. This has made it possible to improve the radiopacifying effect without decreasing excessively the mechanical properties of the resulting acrylic cement.

Nevertheless, the latter bone cements have also proved to be not without
15 drawbacks.

A first disadvantage is the fact that powdery tantalum, in contrast to tantalum in plaque form, is not considered biocompatible according to current regulations. The biocompatibility of tantalum is related to oxygen absorption, a phenomenon which
20 is increased by the considerable specific surface area of the finely divided form necessary for efficient dispersion in the acrylic cement. Even if the cement is prepared immediately before use, it is almost impossible to prevent the oxygen from being absorbed by the metal and to keep its level at values below 300 ppm as required by the current regulations (ISO 13782), and the use of tantalum oxide

is prohibited by the Pharmacopoeia.

A second drawback consists in the fact that the tantalum powder must be prepared by the surgeon at the moment of using it since, due to the sterility and biocompatibility requirements mentioned above, it is practically impossible to purchase tantalum powder in sterile form on the market.

A further drawback consists in the fact that it is difficult to obtain a diameter distribution of the particles forming the fine powder suitable for injection by means of a syringe.

A further drawback consists in the fact that the dispersion phase of the tantalum powder has the tendency to form inclusions of air in the bone cement.

A further drawback consists in the fact that it is extremely difficult to obtain a homogeneous dispersion of the powder in the polymer matrix.

Disclosure of the Invention

A general object of the present invention consists in eliminating the drawbacks of the abovementioned prior art by providing an acrylic bone cement which exhibits improved radiopacity and mechanical strength properties.

A particular object is to provide an acrylic bone cement which has improved

mechanical strength properties, in particular better fatigue behaviour, compared to the known bone cements of the past.

A particular object is to provide an acrylic bone cement which has improved
5 radiopacity properties without the addition of additives consisting only in part of radiopacifiers.

Another particular object of the present invention is to provide a liquid acrylic bone cement, prepared with biocompatible materials without a reduction in
10 biocompatibility.

Another object of the present invention is to provide a liquid acrylic bone cement, prepared in sterile fashion using a sterile or readily sterilizable material.

15 Another object of the present invention is to provide an acrylic bone cement which is particularly suitable for vertebroplasty.

Another object of the present invention is to provide a method for the preparation of an acrylic bone cement which is relatively easy for the surgeon to perform.

20

The aforementioned objects, together with others, which will become clearer hereinafter, are achieved by means of a radiopaque acrylic bone cement for orthopaedic use in accordance with Claim 1, comprising a solid phase essentially composed of a powder of at least one poly(methyl methacrylate)-based polymer,

one free-radical polymerization initiator and one radiopacifying material, and a liquid phase composed of a mixture of at least one monomer, one accelerator and one stabilizer, said solid phase being capable of polymerizing and hardening at the time of mixing with said liquid phase so as to give a bone cement matrix, characterized in that said radiopacifying material comprises metal particles of high molecular weight, mixtures, alloys or compounds thereof, covered with a coating layer of a polymer which is compatible with said matrix and exhibits oxygen barrier characteristics, said coating layer being not completely dissolved in said liquid phase such that its oxygen barrier characteristics are kept at least partly unchanged.

As a result of such a composition, the bone cement exhibits considerable radiopacity achieved by adding a limited amount of a radiopaque contrast agent.

Furthermore, the bone cement possesses mechanical properties which are considerably better than those of the prior art, in which the contrast element is added, but not bonded to the polymer matrix and constitutes an initiating element for fracturing of the polymerized mass.

In the method for preparation of the bone cement, the polymer coating layer of the metal defines at the moment of polymerization a zone of chemical adhesion between the polymer chains being formed and the metal particles. This determines the increase in mechanical properties of the composite in which the metal particles are no longer an element which is not bonded to the polymer

matrix.

This makes it possible to take advantage of the higher ductility of the metallic material compared to the fragility of the polymer material, imparting to the composite as a whole better mechanical properties, especially a better tenacity and fatigue strength.

A further advantage of the bone cement according to the invention consists in the fact that the biocompatible and sterilizable polymer coating layer protects each single tantalum or tungsten metal particle contained in the mixture from exposure to oxygen. This prevents the oxygen from being absorbed, thus avoiding the formation of oxides and overcoming the drawbacks and pharmacological limitations linked to the presence of oxygen.

Even after addition of the solid phase to the liquid phase, this coating, owing to the fact that it is not dissolved completely, retains its function as barrier and protector of the metal present therein.

Moreover, the bone cement can be delivered in the same package as the contrast agent and added directly by the manufacturer to the solid phase in the optimum amount and diametral distribution for the desired application as sterile medical remedy.

A further advantage of the invention is that it is possible to add to the bone cement

active substances, which will be released *in-situ* for the treatment of possible disorders.

A further advantage of the bone cement according to the invention is that it can be
5 formulated with such a fluidity that it can be administered through a cannula having an internal diameter of less than 2 mm.

The device according to the present invention can advantageously be used for the filling of deep and critical bone holes by means of operations with limited
10 invasiveness, for example using percutaneous techniques. Moreover, the use can be extended to zones in which high radiopacity and mechanical properties, not satisfied by the known bone cements, are required.

Using the radiopaque acrylic bone cement according to the invention it is possible,
15 for example, to perform vertebroplasty interventions under absolutely safe conditions, with continuous monitoring of the operation, achieved by administering to the patient a limited amount of X rays and obtaining a hardened support having considerable mechanical strength with respect to the stresses induced during walking.

20

Brief description of the drawings

Further features and advantages of the invention will be more clearly understood from the detailed description of several preferred, but not exclusive embodiments

of the radiopacified acrylic bone cements, furnished by way of a non-limiting example, with reference to the accompanying drawings, in which:

FIG. 1 shows a schematic representation of the bone cement;

FIG. 2 shows a partially sectioned view of a radiopaque metal particle
5 coated with a poly(methyl methacrylate)-based protective polymer;

FIG. 3, FIG. 4 and FIG.5 show SEM (Scanning Electron Microscope) pictures of different amplification. i.e. 1000x, 3000x and 10,000x respectively, of the radiopaque tantalum metal particles as obtained before being coated with the protective polymer;

10 FIG. 6 and FIG. 7 show SEM (Scanning Electron Microscope) pictures of different amplifications, i.e. 3000x and 10,000x, respectively, of the radiopaque tantalum metal particles coated with protective polymer.

Detailed description of preferred exemplary embodiments

15

A radiopaque acrylic bone cement for orthopaedic use according to the invention essentially comprises a solid phase dissolved in a liquid phase.

The solid phase is essentially composed of a mixture of at least one acrylic
20 polymer, for example based on poly(methyl methacrylate), at least one free-radical polymerization initiator and at least one or more substances which are opaque to X rays. More specifically, the mixture can contain poly(methyl methacrylate), poly(methyl methacrylate/styrene), poly(butyl methacrylate) and copolymers thereof and benzoyl peroxide as initiator. Moreover, the solid-phase mixture may

contain one or more pharmacologically active substances.

The liquid phase is essentially composed of a mixture of a monomer, at least one accelerator and at least one stabilizer. More specifically, the monomer can consist
5 of monomethylmethacrylate and the accelerator can consist of N,N-dimethyl-p-toluidine.

Referring to Fig. 1, the hardened bone cement, indicated overall by 1, is composed of a polymer matrix 2 in which irregularly shaped particles 3 composed of
10 radiopaque elements 4 coated with a polymer compatible with the polymer matrix 2 are dispersed homogeneously.

The irregularly shaped particle 3, shown schematically in FIG. 2, is composed of the radiopaque element 4 completely coated with a polymer layer 5 compatible
15 with the matrix 2 and having such a thickness 6 that it does not dissolve completely in the liquid phase during polymerization.

A particular characteristic of the present invention consists in adding radiopaque elements of high molecular weight, greater than 130 Dalton, in the form of metals, mixtures of metals, or metal compounds such as alloys. Indeed, many elements of
20 high atomic weight, for example more than 125 Dalton, are highly radiopaque and thus suitable for use as long as they are non-toxic or can be used in non-toxic form.

Preferably, the radiopaque substances contained in the solid phase comprise tungsten and/or tantalum particles in the form of metals, compounds or mixtures thereof, which particles are covered with a coating layer of a polymer compatible with said bone cement. In place of tantalum or tungsten, it is also possible to use
5 other metals of high atomic weight such as gold, platinum, bismuth or lead.

Ideally the coating layer of the particles is an acrylic polymer based on poly(methyl methacrylate).

- 10 Advantageously, the coating layer can be obtained by adding the polymer based on poly(methyl methacrylate), dissolved in a water-miscible solvent, to an aqueous dispersion of the metal particles from which the surface layer had previously been removed, followed by evaporation of the solvents and drying of said layer.
- 15 The oxygen content of the tantalum metal is preferably less than about 300 ppm.

The diameter of the radiopaque particles coated with poly(methyl methacrylate) can be between about 1 μm and about 150 μm .

- 20 Before depositing the coating, the diameter of radiopacifying metal particles can be between about 1 μm and about 100 μm .

Prior to the deposition of the coating, the radiopacifying particles can have nanometre size, for example a diameter between about 25 nanometres and about

1000 nanometres. In this manner, the diameter of the coated radiopacifying particles, which have a plurality or an aggregate of nanometre-sized metal particles, can be between about 20 μm and about 60 μm , with the noteworthy advantage of a more homogeneous and easier dispersion of said particles in the
5 polymer powder.

Ideally said nanometre-sized metal particles may have been pre-sinterized.

Preferably, the tantalum or tungsten to poly(methyl methacrylate) weight ratio in
10 the particles is between about 95/5 and about 70/30.

The molecular weight of the particle coating polymer can advantageously be between about 20,000 and about 800,000 Dalton.

15 The amount of radiopacifying element can advantageously vary between about 1 and about 20% by weight, relative to the solid phase, and is preferably between about 2% and about 5% by weight, relative to the solid phase.

Advantageously, the solid phase and the coated radiopaque particles can be
20 contained in the same package. Alternatively, the solid phase and the coated radiopaque particles can be contained in different packages.

In the case of a single package, it can consist of a shell containing both the solid phase and the liquid phase. In clinical use, the cement-containing shell is opened,

and its contents consisting of an envelope containing the powder and the vial containing the liquid phase is transferred to the operating room aseptically on a sterile shelf.

- 5 In preparing the cement, the ampoule is opened, and the entire liquid is placed in the mixing bowl, and all the powder is introduced into the liquid. In order to minimize the inclusion of bubbles, the cement must be mixed by moving the spatula from the outside to the centre of the bowl. Since the whole powder must be impregnated with liquid, any solid residues not impregnated with liquid are carefully
10 immersed in the moist mass using the spatula.

At this point, the liquid mass can be transferred into a syringe for *in-situ* injection.

- The radiopacifying powder according to the present invention can be mixed with
15 the solid phase of the bone cement system.

Table 1 shows a few indicative but not exhaustive examples of preferred formulations.

Table 1

20

	Liquid phase (Values in percent by weight)		Solid phase (Values in percent by weight)	
Cemex RX (reference)	Methyl methacrylate	98.20	Poly(methyl methacrylate)	88.00
	N,N-dimethyl-p-toluidine	1.80	Benzoyl peroxide	3.00
	Hydroquinone	75 ppm	Barium sulphate FU	9.00

Cemex XL (reference)	Methyl methacrylate	98.20	Poly(methyl methacrylate)	85.00
	N,N-dimethyl-p-toluidine	1.80	Benzoyl peroxide	3.00
	Hydroquinone	75 ppm	Barium sulphate FU	12.00
Example 1 (reference)	Methyl methacrylate	98.20	Poly(methyl methacrylate)	82.5
	N,N-dimethyl-p-toluidine	1.80	Benzoyl peroxide	3.00
	Hydroquinone	75 ppm	Barium sulphate FU	12.00
			Tantalum as-delivered	2.50
Example 2 (reference)	Methyl methacrylate	98.20	Poly(methyl methacrylate)	67.00
	N,N-dimethyl-p-toluidine	1.80	Benzoyl peroxide	3.00
	Hydroquinone	75 ppm	Barium sulphate FU	30.00
Example 3	Methyl methacrylate	98.20	Poly(methyl methacrylate)	82.00
	N,N-dimethyl-p-toluidine	1.80	Benzoyl peroxide	3.00
	Hydroquinone	75 ppm	Barium sulphate FU	10.00
			PMMA-coated tantalum	5.00
Example 4	Methyl methacrylate	98.20	Poly(methyl methacrylate)	82
	N,N-dimethyl-p-toluidine	1.80	Benzoyl peroxide	3.00
	Hydroquinone	75 ppm	Barium sulphate FU	12.50
			PMMA-coated tantalum	2.50
Example 5	Methyl methacrylate	98.20	Poly(methyl methacrylate)	87
	N,N-dimethyl-p-toluidine	1.80	Benzoyl peroxide	3.00
	Hydroquinone	75 ppm	PMMA-coated tantalum	10.00
Example 6	Methyl methacrylate	98.20	Poly(methyl methacrylate)	82
	N,N-dimethyl-p-toluidine	1.80	Benzoyl peroxide	3.00
	Hydroquinone	75 ppm	Zirconium oxide	10.00

			PMMA-coated tantalum	5.00
Example 7	Methyl methacrylate	98.20	Poly(methyl methacrylate)	80
	N,N-dimethyl-p-toluidine	1.80	Benzoyl peroxide	3.00
	Hydroquinone	75 ppm	Zirconium oxide	14.50
			PMMA-coated tantalum	2.50
Example 8	Methyl methacrylate	98.20	Poly(methyl methacrylate)	86
	N,N-dimethyl-p-toluidine	1.80	Benzoyl peroxide	3.00
	Hydroquinone	75 ppm	Barium sulphate FU	8.50
			PMMA-coated tungsten	2.50
Example 9	Methyl methacrylate	98.20	Poly(methyl methacrylate)	82.00
	N,N-dimethyl-p-toluidine	1.80	Benzoyl peroxide	3.00
	Hydroquinone	75 ppm	Barium sulphate FU	10.00
			PMMA-coated tungsten	5.00
Example 10	Methyl methacrylate	98.20	Poly(methyl methacrylate)	82
	N,N-dimethyl-p-toluidine	1.80	Benzoyl peroxide	3.00
	Hydroquinone	75 ppm	Barium sulphate FU	12.50
			PMMA-coated tungsten	2.50

Using the bone cements prepared by the abovementioned methodology and the formulations listed in Table 1, in accordance ISO standard 5833, ASTM standard F451-99 and ISO standard 527, a few samples were prepared for measuring the compressive strength, the tensile strength, the bending strength and the work at break. The latter, expressed in MJ/m³, is calculated as the integral of the stress/deformation curve obtained in the bending test.

Tables 2, 3 and 4 list the values, expressed in MPa, obtained with the samples.

Table 2

5

	Compression	Standard deviation	Tensile strength	Standard deviation
Cemex RX (reference)	106	7.75	36	4.20
Example 1	108	3.51	38	1.04
Example 3	131	6.68	44	0.14
ISO 5833	> 70		> 30*	

* Limit not present in the regulations

Table 3

10

	Bending	Standard deviation	Modulus of Elasticity	Standard deviation
Cemex RX (reference)	61	4.78	2974	64
Example 1	62	2.09	2850	334
Example 3	70	5.19	2909	102
ISO 5833	> 50		> 1800	

Table 4

	Deformation at break (%)	Standard deviation	Work at break (MJ/m ³)	Standard deviation
Cemex RX (reference)	2.01	0.17	0.88	0.14
Example 2	2.22	0.23	0.79	0.22
Example 3	2.72	0.39	1.11	0.31

The tests were carried out at ambient temperature and humidity. The samples,
 5 prepared according to ISO 5833, were kept in water at 37°C for 48 hours, taken
 out a few minutes prior to the test and deformed at a set speed of 20 mm/min for
 the compression measurements, 10 mm/min for the tensile measurements, and 5
 mm/min for the bending stress measurements.

10 The work at break of the bone cement according to the present invention shows
 an increase of 26%, relative to the value of conventional bone cement and of 40%,
 compared to the bone cement made radiopaque by addition of a vast amount
 (30%) of barium sulphate.

15 Using the bone cements prepared by the abovementioned methodology and the
 formulations listed in Table 1, the values of the chemical and physical properties
 such as viscosity, flow behaviour, doughing time, setting time and the maximum
 polymerization temperature were measured according to ISO standard 5833:92
 and ASTM standard F451-99. The values obtained are listed in Tables 5 and 6.

Table 5

	Viscosity η'_{4} (Pa*s)	Doughing time (DT) (min)	Setting time (ST) (min)	Maximum temperature (°C)
Cemex XL	13,900 ± 2970	4' 55"	12'50"	64
Example 4	27,000 ± 1414	9' 30"	16'00"	72
ISO 5833		< 5'	< 15'	< 90

The value η'_{4} , of the apparent dynamic viscosity at 4' from mixing, measured at
 5 22°C and a humidity of 32%, is customarily taken as a descriptive parameter of the
 rheological behaviour of the material.

The measurements of DT, ST and the maximum polymerization temperature were
 performed in a laboratory temperature-controlled at 23°C ± 1 and at a relative
 10 humidity greater than 40%, using material which, in turn, was left in a thermostat
 under the same conditions for at least 16 hours.

Table 6

	Flow behaviour (g)	Standard deviation	% by weight
Cemex XL	60.5	0.70	89
Example 4	58		85

The flow behaviour represents the mass of cement, expressed in grams, which flows from the inclined mixing bowl at 90°C in 60 seconds after 1' and 30" from the beginning of mixing.

- 5 The bone cement according to the present invention exhibits very high properties in all stress directions, and in particular the metal additive improves the compressive strength.

In all cases, the materials have exceeded the limits required by the regulations
10 and thus, from a mechanical point of view, fall entirely within the class of bone cements.

The polymerization temperature is increased in the tantalum material even though it is still substantially below the values required by the standards.

15

It must be pointed out that the bone cement according to the invention can advantageously be used for surgical interventions in vertebroplasty by means of percutaneous *in-situ* injection of the cement or else for surgical interventions of osteosynthesis in which superior radiopacity and mechanical properties are
20 required.

CLAIMS

1. Radiopaque acrylic radiopaque bone cement for orthopaedic use, comprising a solid phase essentially composed of a powder of at least one poly(methyl acrylate)-based polymer, one free-radical polymerization initiator and one radiopacifying material, and a liquid phase substantially composed of a mixture of at least one monomer, one accelerator and one stabilizer, said solid phase being capable of polymerizing and hardening upon mixing thereof with said liquid phase so as to give a bone cement matrix, characterized in that said radiopacifying material comprises metal particles of high molecular weight, mixtures, alloys or compounds thereof, covered with a coating layer of a polymer which is compatible with said matrix and exhibits oxygen barrier properties, said coating layer being not completely dissolved in said liquid phase so as to keep its oxygen barrier properties at least partly unchanged.

15

2. Acrylic bone cement according to Claim 1, characterized in that said metals of high molecular weight have a molecular weight of more than 130 Dalton.

3. Acrylic bone cement according to Claim 2, characterized in that said metals of high molecular weight are tantalum and tungsten.

20

4. Acrylic bone cement according to Claim 2, characterized in that said metals of high molecular weight are selected in such a way as to have an oxygen content of less than 300 ppm by weight.

5. Acrylic bone cement according to Claim 1, characterized in that said coating layer of said metal particles is a poly(methyl methacrylate)-based polymer.

6. Acrylic bone cement according to Claim 1, characterized in that each
5 single uncoated metal particle has an average diameter of between about 1 μm and about 100 μm .

7. Acrylic bone cement according to Claim 1, characterized in that each
single coated metal particle has an average diameter of between about 1 μm and
10 about 150 μm .

8. Acrylic bone cement according to Claim 1, characterized in that said acrylic polymer coating layer covers each single metal particle.

15 9. Acrylic bone cement according to Claim 1, characterized in that said acrylic polymer coating layer covers an aggregate of previously synthesized nanometre-sized metal particles.

10. Acrylic bone cement according to Claim 9, characterized in that said
20 metal particles of said aggregate have an average diameter of between about 25 nm and about 1000 nm.

11. Acrylic bone cement according to Claims 6 to 10, characterized in that said coated metal particles have a distribution of diameters with a relatively

low standard deviation so as to impart to the powder a high flowing capability and make the cement fluid prior to its hardening.

12. Acrylic bone cement according to Claim 2, characterized in that the
5 molecular weight of the coating polymer of said particles which is compatible with said bone cement is between about 20,000 and about 800,000 Dalton.

13. Acrylic bone cement according to Claim 2, characterized in that the
molecular weight of the coating polymer of said particles which is compatible with
10 said bone cement is between about 300,000 and about 800,000 Dalton.

14. Acrylic bone cement according to Claim 2, characterized in that the
weight ratio between the metal contained in said particles and their coating
polymer is between about 95:5 and about 70:30.

15

15. Acrylic bone cement according to one or more of the preceding
claims, characterized in that the amount of the radiopacifying agent is between
about 1 and about 20% by weight, relative to the solid phase.

20

16. Acrylic bone cement according to Claim 15, characterized in that the
amount of radiopacifying agent is preferably between about 2% and about 5% by
weight, relative to the solid phase.

17. Acrylic bone cement according to one or more of the preceding

claims, characterized in that said solid phase further comprises one or more pharmacologically active substances.

18. Acrylic bone cement according to one or more of the preceding
5 claims, characterized in that said solid phase and said coated radiopaque particles are contained in the same package.

19. Acrylic bone cement according to one or more of the preceding
claims, characterized in that said solid phase and said coated radiopaque particles
10 are contained in separate packages.

20. Acrylic bone cement according to one or more of the preceding
claims, characterized in that said solid phase comprises poly(methyl
methacrylate), poly(methyl methacrylate/styrene), poly(butyl methacrylate) and
15 copolymers thereof.

21. Method for preparing a radiopaque acrylic bone cement for
orthopaedic use, comprising the steps of:

- preparing a solid phase essentially composed of a powder of at least one
20 free-radical poly(methyl methacrylate)-based polymer, one polymerization initiator
and one radiopacifying material;
- preparing a liquid phase composed of a mixture of at least one monomer,
one accelerator and one stabilizer,
- mixing said solid phase with said liquid phase so as to perform

polymerization in such a way that a bone cement matrix is obtained;

- in which the radiopacifying material is obtained by preparing a powder of metal particles of high molecular weight, mixtures, alloys or compounds thereof, and coating said particles with a layer of a polymer which is compatible with said matrix and exhibits oxygen barrier properties, said coating layer not being completely dissolved in said liquid phase so as to keep its oxygen barrier properties at least partly unchanged.

22. Method according to Claim 21, characterized in that said coating layer of said metal particles is obtained by adding said polymer, dissolved in water-miscible organic solvents, to an aqueous dispersion of said radiopaque metal particles, followed by evaporation and drying of said solvents.

23. Method according to Claim 22, characterized in that said metal particles, before being coated, are subjected to a step of removal of their surface layer.

24. Use of the bone cement according to one or more of Claims 1 to 20 for surgical vertebroplasty interventions by means of percutaneous in-situ injection of cement.

25. Use of the bone cement according to one or more of Claims 1 to 20 for surgical osteosynthesis interventions in which superior radiopacity and mechanical properties are required.




FIG. 1




FIG. 2

2/4


BEST AVAILABLE COPY



Powder of Tantalum un-coated

mag=1000x

FIG. 3




Powder of Tantalum un-coated

mag=3000x

FIG. 4

3/4




Powder of Tantalum un-coated

mag=10000x


FIG. 5

4/4



Powder of Tantalum coated with the Poly (methyl methacrylate)

mag=3000x

FIG. 6

Powder of Tantalum coated with the Poly (methyl methacrylate)

mag=10000x

FIG. 7

INTERNATIONAL SEARCH REPORT

National Application No

PCT/IB 02/01860

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61L24/00 A61L27/44 A61L27/54 A61F2/44 A61L27/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 04924 A (DRAENERT KLAUS) 2 April 1992 (1992-04-02) page 1 -page 8, line 3 examples 1-3 figure 1 claims 1-9,11,14-17,23 ---	1-15,17, 18,20-25
X	EP 0 041 614 A (BAYER AG) 16 December 1981 (1981-12-16) page 1, line 1 - line 22 page 2, line 6 - line 17 page 3, line 6 - line 8 page 5, line 3 -page 6, line 24 claims 1,3,4,7-9 --- -/--	1-4, 6-15, 20-22, 24,25

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

30 September 2002

Date of mailing of the international search report

11/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hars, J

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IB 02/01860

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 336 699 A (COOKE FRANCIS W ET AL) 9 August 1994 (1994-08-09) column 4, line 46 -column 7, line 4 column 8, line 28 - line 31 column 8, line 64 - line 2 figure 3 claims 1,5,18-23,28,39-44,70-73,75-77 -----	1-15, 17-25
A	WO 99 18894 A (PARALLAX MEDICAL INC ;PREISSMAN HOWARD (US)) 22 April 1999 (1999-04-22) page 1, line 12 -page 5, line 30 page 8, line 11 - line 13 examples 1,2 claims 1-3,19,20,22,23,25-28,33-35,37 -----	1-25
A	US 5 574 075 A (DRAENERT KLAUS) 12 November 1996 (1996-11-12) column 2, line 44 - line 57; claims 1,6,7 -----	1-25

INTERNATIONAL SEARCH REPORT

ernational application No.
PCT/IB 02/01860

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 24 and 25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/01860

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9204924	A	02-04-1992	DE 4029714 A1	26-03-1992
			WO 9204924 A1	02-04-1992
			EP 1240908 A1	18-09-2002
			EP 0548193 A1	30-06-1993
			JP 6500718 T	27-01-1994
			US 6080801 A	27-06-2000
EP 0041614	A	16-12-1981	DE 3018966 A1	10-12-1981
			DE 3161763 D1	02-02-1984
			EP 0041614 A1	16-12-1981
			JP 57007827 A	16-01-1982
US 5336699	A	09-08-1994	US 5476880 A	19-12-1995
			AU 3433393 A	13-09-1993
			CA 2129974 A1	02-09-1993
			EP 0626834 A1	07-12-1994
			WO 9316661 A1	02-09-1993
WO 9918894	A	22-04-1999	US 6309420 B1	30-10-2001
			AU 1081999 A	03-05-1999
			WO 9918894 A1	22-04-1999
			US 6231615 B1	15-05-2001
			US 2001012968 A1	09-08-2001
US 5574075	A	12-11-1996	DE 4033343 A1	23-04-1992
			AT 202713 T	15-07-2001
			AU 8732791 A	20-05-1992
			DE 59109215 D1	09-08-2001
			WO 9206717 A1	30-04-1992
			EP 0555261 A1	18-08-1993
			JP 6502086 T	10-03-1994

THIS PAGE BLANK (USPTO)